Literature DB >> 28778707

Cancer and autoimmune diseases.

Eitan Giat1, Michael Ehrenfeld2, Yehuda Shoenfeld3.   

Abstract

PURPOSE OF REVIEW: The association between autoimmunity and cancer is well established. Cancer has been implicated in some autoimmune disorders (AID), such as scleroderma and myositis. On the other hand, many autoimmune disorders and immunosuppressive therapy, have been linked to an increased risk for cancer. We reviewed the accumulating data on the association between autoimmunity and cancer during the past three years, with an emphasis on large cohorts, as well as concept changing discoveries in the association of cancer and auto-immunity. RECENT
FINDINGS: Recent published data from large registries and databases have changed our perspective on the association of AID and cancer, as well as the presumed association between anti-tumor necrosis factor (anti -TNF) therapy and certain malignancies, suggesting a small to no increase in almost all types of cancers. Similarly, the increased risk of malignancies in some AID, such as Sjogren's syndrome (SS) and lupus, may be different from previous estimations. New associations with malignancies were discovered, such as IgG4 related disease, Behcet's and sarcoidosis, which were not clearly associated with cancer in the past. These newly described associations may have clinical implications and contribute to our understanding of both autoimmunity and cancer. Similarly, we reviewed studies of autoimmunity secondary to malignancy, and the concomitant appearance of cancer with autoimmune disease, such as the discovery of a specific mutation in scleroderma (SS) patients that developed cancer, which establishes the association between these disorders and sheds light on the pathology behind this association.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Auto-immune disease; Cancer; Malignancy; Rheumatic disease

Mesh:

Year:  2017        PMID: 28778707     DOI: 10.1016/j.autrev.2017.07.022

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  41 in total

1.  Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival.

Authors:  Abdulla Watad; Dennis McGonagle; Nicola L Bragazzi; Shmuel Tiosano; Doron Comaneshter; Yehuda Shoenfeld; Arnon D Cohen; Howard Amital
Journal:  Oncoimmunology       Date:  2019-03-24       Impact factor: 8.110

2.  Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity.

Authors:  Julio C Valencia; Nkolika Egbukichi; Rebecca A Erwin-Cohen
Journal:  J Interferon Cytokine Res       Date:  2018-12-18       Impact factor: 2.607

3.  Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina.

Authors:  Martin Brom; Sebastian Moyano; Ignacio J Gandino; Marina Scolnik; Enrique R Soriano
Journal:  Rheumatol Int       Date:  2019-08-30       Impact factor: 2.631

Review 4.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

5.  Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Authors:  Alessio Cortellini; Sebastiano Buti; Daniele Santini; Fabiana Perrone; Raffaele Giusti; Marcello Tiseo; Melissa Bersanelli; Maria Michiara; Antonino Grassadonia; Davide Brocco; Nicola Tinari; Michele De Tursi; Federica Zoratto; Enzo Veltri; Riccardo Marconcini; Francesco Malorgio; Carlo Garufi; Marco Russano; Cecilia Anesi; Tea Zeppola; Marco Filetti; Paolo Marchetti; Andrea Botticelli; Gian Carlo Antonini Cappellini; Federica De Galitiis; Maria Giuseppa Vitale; Roberto Sabbatini; Sergio Bracarda; Rossana Berardi; Silvia Rinaldi; Marianna Tudini; Rosa Rita Silva; Annagrazia Pireddu; Francesco Atzori; Rita Chiari; Biagio Ricciuti; Daniela Iacono; Maria Rita Migliorino; Antonio Rossi; Giampiero Porzio; Katia Cannita; Valeria Ciciarelli; Maria Concetta Fargnoli; Paolo Antonio Ascierto; Corrado Ficorella
Journal:  Oncologist       Date:  2019-02-22

Review 6.  Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

Authors:  Shaheen Khan; David E Gerber
Journal:  Semin Cancer Biol       Date:  2019-07-19       Impact factor: 15.707

7.  Cancer risk in tuberculosis patients in a high endemic area.

Authors:  Guang-Liang Chen; Li Guo; Shun'e Yang; Dong-Mei Ji
Journal:  BMC Cancer       Date:  2021-06-09       Impact factor: 4.430

8.  Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies.

Authors:  Iñigo Les; Mireia Martínez; Alicia Narro; Inés Pérez; Cristina Sánchez; Laura Puntí; Pilar Anaut; Saioa Eguiluz; Alberto Herrera; Severina Domínguez
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 9.  Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction.

Authors:  Vaia Florou; Sonam Puri; Ignacio Garrido-Laguna; Breelyn A Wilky
Journal:  Ann Transl Med       Date:  2021-06

10.  High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury.

Authors:  Li Dong; Yu-Min Zheng; Xiao-Guang Luo; Zhi-Yi He
Journal:  J Inflamm Res       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.